Last updated September 9, 2026
Key finding
In the JADE-PRISM group, 104 participants (23.8%) versus 54 in the JADE-only group (12.2%; P < 0.001) reached three or more treatment targets.
The PRISM study evaluated the effectiveness of the JADE-PRISM intervention compared to usual care in diabetes management, finding significant improvements in treatment target attainment and emotional distress.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
The PRISM study evaluated the effectiveness of the JADE-PRISM intervention compared to usual care in diabetes management, finding significant improvements in treatment target attainment and emotional distress.
These findings are significant as they suggest that the JADE-PRISM intervention can lead to better management of diabetes by helping patients achieve more treatment goals and improve their emotional well-being. This could enhance the quality of life for individuals living with diabetes and inform future clinical practices.
The study's effectiveness measures were unclear for some outcomes. The sample size may limit the generalizability of the findings. No significant improvements were observed in the JADE-only group.
Published in
Publication details and source links for this paper.
Andrea OL, Chun KO, Baoqi F, et al. The Precision Medicine to Redefine Insulin Secretion and Monogenic Diabetes (PRISM) study. Diabetes Care. 2026;49(7):1202-1212. doi:10.2337/dc26-0114
In the JADE-PRISM group, 104 participants (23.8%) reached three or more treatment targets compared to 54 (12.2%) in the JADE-only group (P < 0.001).
Improved proxies of β-cell function were observed in the JADE-PRISM group.
Reduced emotional distress was reported in the JADE-PRISM group.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Joint Asia Diabetes Evaluation (JADE)-PRISM, Usual care and Attainment of three or more treatment targets, Beta-cell function, Exploratory patient-reported measures, and 1 more.
This study contributes evidence to
Primary intervention
Joint Asia Diabetes Evaluation (JADE)-PRISM
Primary outcomes
Evidence topics
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
1
Related topics
8
Evidence pairs
21
Related studies
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence topic
matched_outcome
Core evidence
The primary outcomes reported in this study.
Joint Asia Diabetes Evaluation (JADE)-PRISM → Attainment of three or more treatment targets
Joint Asia Diabetes Evaluation (JADE)-PRISM → Attainment of three or more treatment targets
Joint Asia Diabetes Evaluation (JADE)-PRISM → Beta-cell function
Joint Asia Diabetes Evaluation (JADE)-PRISM → Beta-cell function
Joint Asia Diabetes Evaluation (JADE)-PRISM → Exploratory patient-reported measures
Joint Asia Diabetes Evaluation (JADE)-PRISM → Exploratory patient-reported measures
Joint Asia Diabetes Evaluation (JADE)-PRISM → Incident diabetes risk
Joint Asia Diabetes Evaluation (JADE)-PRISM → Incident diabetes risk
Usual care → Attainment of three or more treatment targets
Usual care → Attainment of three or more treatment targets
Usual care → Exploratory patient-reported measures
Usual care → Exploratory patient-reported measures
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Joint Asia Diabetes Evaluation (JADE)-PRISM and Attainment of three or more treatment targets, Joint Asia Diabetes Evaluation (JADE)-PRISM and Beta-cell Function.
This study contributes to the evidence on the following intervention-outcome relationships.
Behavioral & Lifestyle
Behavioral & Lifestyle
Curated evidence collections and hubs this study is part of.
All studies measuring Attainment of three or more treatment targets
Measures Attainment of three or more treatment targets as a key outcome.
All studies measuring Beta-cell Function
Measures Beta-cell Function as a key outcome.
All studies on Joint Asia Diabetes Evaluation (JADE)-PRISM
Contributes to Joint Asia Diabetes Evaluation (JADE)-PRISM evidence base.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
Joint Asia Diabetes Evaluation (JADE)-PRISM appears to improve attainment of three or more treatment targets.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Attainment of three or more treatment targets
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Joint Asia Diabetes Evaluation (JADE)-PRISM appears to improve beta-cell function.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Beta-cell function
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Joint Asia Diabetes Evaluation (JADE)-PRISM appears to improve exploratory patient-reported measures.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Exploratory patient-reported measures
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear reduction in incident diabetes risk with Joint Asia Diabetes Evaluation (JADE)-PRISM.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Incident diabetes risk
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
